Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 79,351 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Youth Drinking, Alcohol Drinking
Interventions: Mobile-delivered personalized feedback; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 29 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: HCV Infection
Interventions: ABT-072, ketoconazole, Placebo; Drug · Other
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Photoaging
Interventions: Laser Therapy, Basic Skin Care Regimen, Lytera; Device · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: TA-65MD, Placebo; Dietary Supplement · Other
Lead sponsor: Telomerase Activation Sciences, Inc; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Springfeild, Missouri

Conditions: Palliative Care
Interventions: Meaning Centered Group Psychotherapy, Supportive Group Psychotherapy; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Radiation Retinopathy, Macular Edema
Interventions: Aflibercept every 2 months, Aflibercept monthly; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: St Louis, Missouri • Houston, Texas

Conditions: COVID-19
Interventions: NDV-HXP-S-KP.2, COVID-19 mRNA Vaccine; Biological
Lead sponsor: CastleVax Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Colorado Springs, Colorado • Burlington, Massachusetts

Conditions: Radiculopathy
Interventions: Lenalidomide (CC-5013); Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 23
States / cities: Phoenix, Arizona • Tucson, Arizona • Loma Linda, California + 20 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, Insulin aspart, Supplemental insulin aspart; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Systemic Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more

Conditions: Urinary Tract Infections
Interventions: BioNourish, a component of Flourish HEC; Device
Lead sponsor: Vaginal Biome Science; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lymphoma
Interventions: AMG 531, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Methotrexate, Cytarabine, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN), HNSCC, Neoplasm Recurrence, Local, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: TMV Vaccine, Toripalimab-tpzi; Biological
Lead sponsor: Metaclipse Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Biliary Tract Cancers
Interventions: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Kidney Disease
Interventions: Education worksheet; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Canton, Michigan • Northville, Michigan

Conditions: Soft-tissue Sarcoma
Interventions: TAK-228; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lung Cancer
Interventions: Erlotinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: 18F-DCFPyL; Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cancer
Interventions: PTC596; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Boston, Massachusetts • Durham, North Carolina • Nashville, Tennessee

Conditions: Digital Intervention, Bibliotherapy
Interventions: Digital technology, Bibliotherapy; Device · Other
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Healthy
Interventions: Abrika Bupropion 150 mg XL Tablet, single dose, Wellbutrin XL® 150 mg Tablet, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Peripheral Vascular Diseases
Interventions: Moderate Intensity, Normal Volume Exercise Training, High Intensity, Normal Volume Exercise Training, Moderate Intensity, High Volume Exercise Training; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Chronic Heart Failure
Interventions: BAY2413555 Dose 1, BAY2413555 Dose 2, Placebo to BAY2413555; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia • Silver Spring, Maryland • Camp Hill, Pennsylvania

Conditions: Healthy
Interventions: Olanzapine; Drug
Lead sponsor: Dost Ongur; Other
Eligibility: 21 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Belmont, Massachusetts

Search by objective public record fields.

Alcohol Feedback, Reflection and Morning Evaluation

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C

Combination Versus Laser Treatment Only

Effect of TA-65MD on Healthy Volunteers

Randomized Controlled Trial of Group Psychotherapy Interventions for Cancer Patients

Intravitreal Aflibercept Injection for Radiation Retinopathy

Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy

Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes

Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)

Effects of Flourish on Recurrent Urinary Tract Infection

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Multi-disciplinary Participatory Design of a Process to Deliver a CKD Diagnosis in Primary Care

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC

18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer

PTC596 in Patients With Advanced Solid Tumors

Digital Support Intervention for Pregnant People with Opioid Use Disorders

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions

Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 2

A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)

The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals